Form 8-K - Current report:
SEC Accession No. 0001178913-25-002045
Filing Date
2025-06-03
Accepted
2025-06-03 16:05:43
Documents
13
Period of Report
2025-06-03
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K zk2533312.htm   iXBRL 8-K 54660
  Complete submission text file 0001178913-25-002045.txt   230695

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250603.xsd EX-101.SCH 4740
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250603_def.xml EX-101.DEF 18263
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250603_lab.xml EX-101.LAB 27748
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250603_pre.xml EX-101.PRE 20505
16 EXTRACTED XBRL INSTANCE DOCUMENT zk2533312_htm.xml XML 6552
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 251019381
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)